Andrin Oswald

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA.

Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France.

Bank Respublika JSC provides banking products and services to individual and corporate clients. It banking segment offers private banking services, including private customer current accounts, savings, deposits, investment savings products, custody, credit and debit cards, consumer loans, and mortgages. It also provides other banking services, including cash and settlement services, plastic cards, money transfers, payments, Internet banking, online loan payments, safekeeping boxes and insurance and reinsurance services. Bank Respublika was founded on May 22, 1992 and is headquartered in Baku, Azerbaijan.

SFPI-FPIM SA/NV operates as a state-owned investment company. It engages in investments in public and private companies in economic and cross-cutting sectors such as sustainable development, innovation, airport and aviation, real estate, and ageing of the population. The company was founded on November 1, 2006 and is headquartered in Brussels, Belgium.

Nanocyl SA specializes in manufacturing of industrial multiwall carbon nanotubes. It produces synthetic materials and manufacture equipments for the automotive and electronic industries. It products include Plasticyl, Epocyl, Aquacyl, Elastocyl, Orgacyl and research grades. The firm also develops tailor made solutions for the aeronautic, construction, sports, and marine industries. The company was founded in 2002 and is headquartered in Sambreville, Belgium.

Maison de la Radio Flagey SA manages spaces intended for cultural activities. The company was founded by Baron Berghmans in 1998 and is headquartered in Ixelles, Belgium.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Banque Lombard Odier & Cie. SA provides financial services. The firm specialized in asset and wealth management, institutional asset management, and private banking services. It has a network of 24 offices in 17 countries. The company was founded in 1796 and is headquartered in Geneva, Switzerland.

SFPI FPIM /PRIVATE EQUITY/ (SFPI FPIM) is the private equity division of SFPI-FPIM SA/NV, which is ultimately-owned by the state of Belgium. The firm was founded in 1994, and is headquartered in Brussels, Belgium.

InDevR, Inc. develops and delivers analytical tools for detection and characterization of biological molecules and microorganisms. The firm offers on the ampliPHOX Colorimetric Detection platform and Custom Arrays to enable its customers a low risk means to explore the high utility of focused microarrays. The company was founded by Kathy L. Rowlen, Laura Kuck and John W. Birks in 2003 and is headquartered in Boulder, CO.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements.

Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY.

Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray.

IanTech, Inc. develops ophthalmic devices for cataract surgery. Its products include miLoop, miPhaco, miMissions, and miResources. The company was founded by Luke Clauson and Sean Ianchulev and is headquartered in Reno, NV.

Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom.

Frontier Nutrition, Inc. develops and manufactures fortified packaged food. Its recipes are localized for traditional diets, taste, and nutrition. The company was founded by Eddie Bearnot and Tanveer Ali on August 18, 2016 and is headquartered in DE.

Precision For Medicine, Inc. provides clinical research focusing on genomics, immune-response assays, global specimen logistics, and biomaker analytics. The company was founded by Ethan D. Leder and Mark P. Clein in 2012 and is headquartered in Chevy Chase, MD.

Avestria Ventures Management LLC (Avestria Ventures) is a venture capital firm founded in 2018 by Linda M. Greub and Corinne H. Nevinny. The firm is headquartered in San Francisco, California.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Autohaus Härtel GmbH is a car dealership located in Osnabrück, Germany. The German company specializes in selling new and used Volkswagen and Volkswagen commercial vehicles. The private company was founded in 1950 by Karl Härtel and is currently led by CEOs Richard Härtel, Martin Graeß, and Christian Hartel.

Quantoom Biosciences SA is a Belgian company that is focused on revolutionizing mRNA production through the development of their platform, ntensify. The private company is based in Nivelles, Belgium. This platform includes DNA amplification and RNA manufacturing, with the ntensify systems being the core of their RNA production technology. The company is made up of a team of scientists, engineers, and clinicians who are dedicated to addressing the major challenges in DNA and RNA production for vaccines and therapeutics.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023.